Background-Mutations in SCN5A are identified in Ϸ20% to 30% of probands affected by Brugada syndrome (BrS).
B rugada syndrome (BrS) is an inherited arrhythmia syndrome with an increased risk of sudden death, resulting from polymorphic ventricular tachycardia and/or ventricular fibrillation in the absence of gross structural abnormalities. 1 BrS is associated with ST-segment elevation in the right precordial ECG leads, which have such a characteristic shape (so-called type I ECG, here abbreviated as "BrS-ECGϩ," see Methods) that their presence is required for the diagnosis. A BrS-ECGϩ may occur spontaneously or be provoked by sodium channel blocking drugs. Although BrS and a BrS-ECGϩ are intimately linked, not all patients with a BrS-ECGϩ are at risk of ventricular fibrillation, as individuals with a BrS-ECGϩ exhibit marked phenotypic variability, ranging from sudden death victims to individuals in whom a BrS-ECGϩ is found by chance, but who remain asymptomatic. 2 The phenotypic variability has spawned studies aimed at finding modifying factors such as gender, age, and other environmental factors. 3, 4 Recent experimental studies support a role of the genetic background, although clinical observations indicate that the risk of sudden death of a BrS patient is not increased if otherwise unexplained sudden death has occurred in his/her family. 5, 6 (GPD1L, CACNA1C, CACNB2, SCN1B, and KCNE3) have been associated with BrS, but the prevalence of variants in these genes is yet unknown. 9 -12 SCN5A mutations may also lead to progressive cardiac conduction defects, long-QT syndrome type 3, or atrial standstill. [13] [14] [15] Progressive cardiac conduction defects and BrS are both associated with a loss of function of the mutant sodium channel. Accordingly, "overlap" families who present a mixed phenotype with features of both diseases exist. 16 -18 The causality of SCN5A mutations in progressive cardiac conduction defects was proven by linkage analysis. 13, 16, 19 In contrast, SCN5A mutations in BrS were discovered by a candidate gene approach 20 and linkage data are still lacking, with the exception of a large overlap family in which the causal mutation is linked with a mixed phenotype. 21 Of note, not only is the proportion of SCN5A mutation carriers low, but also, conversely, BrS-ECGsϩ were reported among members of SCN5A-positive BrS families who did not carry the familial SCN5A mutation. 22, 23 Clearly, the association between BrS and SCN5A mutations is complex. In this study, we set out to investigate this association in a larger group of families.
Methods
This retrospective study was conducted at the center of reference for rare arrhythmic diseases of Nantes University Hospital and at the Academic Medical Center, University of Amsterdam, in accordance with the local guidelines for genetic research and with the approval of the local medical ethics committees. Informed written consent was obtained from all patients.
Large genotyped BrS families in which 5 or more family members carried a SCN5A mutation were included for the present investigation. An individual was defined as affected by BrS if he/she displayed a BrS-ECG at baseline or after provocation with a class I antiarrhythmic drug (BrS-ECGϩ). 24 A BrS-ECGϩ was defined as a coved-type ST-segment elevation Ն0.2 mV at its peak followed (without isoelectric separation) by a negative T wave in 2 or more right precordial leads. 25 Either intravenous ajmaline (1 mg/kg body weight at a rate of 10 mg/min) or flecainide (2 mg/kg body weight in 10 minutes with a maximum of 150 mg) were used for drug testing. Drug challenge was not performed in patients younger than 16 years of age and in those showing severe conduction defects at rest. Underlying structural heart disease was excluded by echocardiography, chest roentgenogram, and exercise testing. Laboratory tests excluded acute ischemia and metabolic or electrolyte disturbances.
ECG parameters that were analyzed, before and after drug testing, were as follows: heart rate, PQ interval (in lead II), QRS duration, maximal ST elevation (right precordial leads), and QTc duration in V4 (Bazett's formula).
Genetic Analysis
Genomic DNA was extracted from peripheral blood leukocytes using standard protocols. All 28 exons of SCN5A were amplified by polymerase chain reaction using intronic primers. 26 Polymerase chain reaction products were screened for a SCN5A mutation using denaturing high performance liquid chromatography-DNA sequencing. DNA variants were disease-causing mutations, rather than polymorphisms, if they were present in highly conserved regions of SCN5A and absent in 200 control individuals. Annotation of mutations was based on the cDNA reference sequence GenBank NM_198056. Sequencing of the SCN5A gene was performed in probands and in all mutation-negative BrS-ECGϩ patients.
Statistical Analysis
ECG parameters were compared with Student t test. Clinical data are expressed as mean valueϮSD for continuous data or proportions for categorical data. A probability value Ͻ0.05 was considered significant.
Results

Clinical and Electrocardiographic Results
Among a total of 444 genotyped probands with BrS-ECGsϩ in whom molecular screening was conducted in our international multicenter database, 118 (26%) carried an SCN5A mutation. Thirteen of them, each with a different mutation (Table 1) , belonged to large families with Ն5 SCN5Apositive members. For this analysis, all the screened members of these 13 families were included, and they constituted the study population (nϭ264; Table 2 ). A history of sudden cardiac death at young age was present in 3 families. In the 13 probands, the workup that led to the diagnosis of BrS was conducted because of (1) unexplained syncopal episode (5) ECG performed because of a family history of sudden death (nϭ1). Eleven of 13 probands had a spontaneous BrS-ECGϩ (type I), whereas 1 showed a BrS-ECGϩ only after drug provocation (family D; Figure 1 ). The last proband (family L) suffered from sudden cardiac death during car racing; his brother also died during car racing from sudden cardiac death and that second event initiated familial screening. Genetic analysis of the probands' relatives identified a total of 115 carriers (Figure 1 ) of the familial SCN5A mutation and 149 mutation negative relatives (mutation negative unaffected individuals not shown in Figure 1 ). In total, a spontaneous BrS-ECGϩ was present in 21 of 115 mutation carriers (18%) and in 3 of the noncarriers. Provocation testing, performed in 67 mutation carriers and 63 noncarriers, was positive in 33 additional mutation carriers and in 5 noncarriers. Thus, among carriers of the familial mutation the penetrance of the BrS phenotype increased from 18% at baseline to 61% after drug testing (54/88 patients). Twenty-five mutation carriers received an implantable cardioverter/ defibrillator.
At baseline, mutation carriers had, on average, significantly longer PR (193Ϯ37 ms versus 162Ϯ29 ms, PϽ0.00001) and QRS intervals (113Ϯ20 versus 95Ϯ14 ms, PϽ0.0001), compared with the noncarriers ( Table 2 ). There was a higher proportion of patients affected by a first-degree AV block among carriers (27/115, 23%) than among noncarriers (4/149, 3%, PϽ0.001) and a higher proportion of patients affected by a complete right bundle branch block among carriers (23/115, 20%) than among noncarriers (5/149, 3%, PϽ0.001).
Results in the Families With Individuals Who Had a BrS-ECG؉ but Did Not Carry the Familial Mutation (Mutation Negative BrS-ECG؉)
In 5 of the13 studied families, 8 individuals showed a BrS-ECGϩ, but did not carry the familial mutation (mutation negative BrS-ECGϩ individuals; Figure 2 ). Among them, 3 (each from a different family) had a spontaneous BrS-ECGϩ, whereas 5 had a BrS-ECGϩ only after drug testing. One was symptomatic (syncope; d2), whereas the other 7 were asymptomatic (3 men and 4 women). Drugs or factors leading to acquired Br-ECGϩ have been excluded in these 8 individuals. 24, 31 These 5 families were composed of 44 mutation-positive and 61 mutation-negative subjects in total (mutation-negative BrS subjects not shown in Figure 1 ). Also in this subgroup, mutation-positive individuals had, on average, significantly longer PR intervals (180Ϯ32 ms versus 158Ϯ25 ms, Pϭ0.001) and QRS durations (107Ϯ18 ms versus 94Ϯ15 ms, PϽ0.0001) than mutation-negative individuals. Among the noncarriers of these families, there were no significant differences in conduction parameters between the subjects showing a BrS ECG and the ones without ST segment elevation (PR: 165Ϯ18 ms versus 157Ϯ26 ms, Pϭ0.3; QRS: 98Ϯ14 ms versus 94Ϯ15 ms, Pϭ0. 4 ).
An electrophysiological study was performed in 5 BrS-ECG nonmutation patients. The mean HV interval was 50 ms. Ventricular tachyarrhythmias were inducible in 3 (1 with a spontaneous BrS-ECG and 2 with a BrS-ECG induced by ajmaline). Signal-averaged ECG was performed in all the mutation negative BrS-ECGϩ patients and was negative in all. An implantable cardioverter/defibrillator was implanted in these 3 patients. No arrhythmic event was registered during a 52Ϯ42 months follow-up period.
Genetic Analysis in the Mutation Negative BrS-ECG؉ Patients
To make sure that the BrS phenotype identified in these patients was not related to another mutation of the SCN5A gene, we have performed a complete sequencing of the SCN5A gene. This sequencing failed to identify any mutation.
Discussion
We set out to investigate the association between the occurrence of a BrS-ECGϩ and carriership of a SCN5A mutation.
For this purpose, we studied 13 families with BrS-ECGsϩ in whom at least 5 family members carried the familial SCN5A mutation. We found that this association is complex, because BrS-ECGsϩ were only found in 18% of mutation carriers at baseline and in 61% after drug testing, and conversely, 8 individuals had a BrS-ECG, but did not carry the familial mutation.
These observations may suggest that carriership of a SCN5A mutation is not causal to the occurrence of a BrS-ECGϩ. Historically, the putative role of SCN5A mutations in BrS is derived from the identification of loss-of-function mutations in many BrS syndrome patients throughout the world. 20 In general, affected families are small, and genetic linkage data are lacking, with exception of a large family with an overlap syndrome where a sodium channel mutation cosegregated with a complex phenotype. 21 If gene-negative, phenotypepositive patients (as present in 5 of these 13 families) would have been found in the initial years of the genotyping efforts in this disease entity, a causal role for SCN5A would have been probably refuted. Biophysical (patch-clamp) studies of the aberrant gene products (cardiac sodium channels) have consistently demonstrated that their altered functional properties are compatible with the BrS phenotype. 32 All BrSassociated SCN5A mutants reported at present exhibit net loss-of-function which is generally regarded as the inciting pathophysiological mechanism of BrS (yet, whether reduced sodium channel function acts by exacerbating spatial inhomogeneities in depolarization or in repolarization to cause the signature ST elevations of BrS is still controversial). 29 Among mutations found in our 13 families (Table 1) , 2 mutations introduce wrong splice sites (c.612 to 2AϾG and c.3963ϩ2TϾC), 2 are frameshift mutations (c.3816delG and c.1983 to 1993dup), 1 mutation introduces a premature stop codon (p.Arg535X), and 1 mutation causes an in-frame insertion (p.1570-Phe1571insIle). These mutations are all likely to produce nonfunctional sodium channels as usually identified in the BrS. The 7 remaining mutations are missense mutations, 4 of which have been biophysically studied (p.Glu161Lys, 23, 30 p.Gly752Arg, 27, 30 p.Gly1408Arg, 28 and p.Arg225Trp 33 ) and have shown to produce a strong decrease in peak sodium current. Although no functional data are available for the remaining 3 missense mutations (p.Ser1382Ile, p.Leu839Pro, and p.Asn1722Asp), we found that mutation carriers have, on average, longer PR intervals and QRS durations than noncarriers. These findings are consistent with previous reports 17, 30 and suggest that the mutant channels produce less sodium current, as sodium current reduction causes cardiac conduction slowing. Thus, Figure 2 . Electrocardiographic patterns in the mutation negative members affected by the BrS phenotype (mutation negative BrS-ECGϩ). Only leads V1 and V2 are reported for each patient. Patients a1, a2, and m1 had a spontaneous BrS phenotype, and the ECG presented here has been recorded before sodium channel blocker challenge, whereas a type 1 BrS-ECG was revealed after sodium channel blocker administration in patients a3, d1, d2, f1, and i1 (ECGs were recorded at maximum dose of sodium channel blocker).
the apparent lack of association between carriership of a SCN5A variant and a BrS-ECGϩ, as observed in our study population, cannot be explained by the fact that these SCN5A variants are no disease-causing mutations. There is also no reason to believe that the subjects with BrS-ECGϩ, who do not carry the familial SCN5A mutation, have no true BrS. Indeed, among the genotype-negative phenotype-positive patients, 3 in 3 different families had a spontaneous BrS-ECGϩ, whereas 5 had a BrS-ECGϩ only after sodium channel blockers. We have found no other clinical abnormalities to explain the electrocardiographic aspect of BrS. One of these individuals was symptomatic with syncope before the study. Finally, the electrophysiological study induced ventricular fibrillation in 3 of these 5 patients, as previously reported in BrS. 8, 34, 35 A novel notion to emerge from our observation that some patients have a BrS-ECGϩ, but do not carry the familial SCN5A mutation, is that modulating factors within the studied families (genetic background) are sufficiently powerful to evoke a BrS-ECGϩ. These observations are in line with emerging experimental studies, which indicate that disparate genetic backgrounds confer disparate susceptibilities to the effects of a single loss-of-function mutant sodium channel. 6 Clearly, the relevant elements in the genetic background may encompass all proteins and molecules that play a role in the pathophysiology of BrS. For instance, such genes may include not only those that encode ion channel subunits but also those that encode molecules that modify cardiac structure (eg, fibrosis), thereby facilitating arrhythmias. Hence, it seems conceivable that the genetic background in some families is so strongly conducive to the occurrence of a BrS-ECGϩ that a BrS-ECGϩ occurs even in the absence of a SCN5A mutation or drug provocation (spontaneous BrS-ECGϩ). This might point to the fact that a loss-of-function SCN5A mutation, on its own, might not be sufficient to cause BrS but could act like a revelatory factor as sodium channel blocker challenge.
Limitations
All the genes known to be involved in the occurrence of the BrS have not been sequenced. Then it is possible that other gene mutations are responsible for the Brugada within the families presented in the study. A provocation testing has not been performed in all the family members, and then it is possible that we have underestimated the frequency of the BrS within these families.
Conclusion
We provide novel clinical evidence to suggest that genetic background may play a powerful role in the pathophysiology of BrS. These findings add further complexity to concepts regarding the causes of BrS and are consistent with the emerging notion that the pathophysiology of BrS includes various elements beyond mutant sodium channels that produce reduced sodium current.
